Breaking News

Aesica Plans Inhalation Expansion

By Gil Roth | October 14, 2013

Looks to add Lead Technical Centre in Nottingham in 2014

Aesica plans to increase its range of inhalation services and products in development, with a new Lead Technical Centre in Nottingham in the cards. The company has hired skilled staff in this area, worked on commercial development of several inhalation technologies, and is actively partnering with innovative companies and universities to discover and engineer new technologies for commercial applications.

Aesica currently has two new development technologies available to clients, including spray drying techniques delivered through a partnership with Upperton, and a powder filling technology delivered through 3P’s Fill2Weight.

The company's Nottingham site has more than five years of experience developing new generic inhalation products alongside many NCEs for trial. Aesica is increasingly looking to work with clients over the longer term and is concentrating on taking new drug targets through to commercial stage, with the ability to switch easily between initial nebulized products, which permit for low-cost entry to early clinical trials, and dry powder inhalers for use in later clinical trials.

Aesica's management contends that the push into inhalation services responds to client demands for CDMOs to offer a wider range of development technologies, delivery expertise and the ability to take a project to commercialization. In addition, having a portfolio of non-IP-protected products, can enable a CDMO to work with clients on developing a formulation irrespective of delivery mechanism. Re-formulations of generic products is seen an area of strong growth.

Ian Lafferty, site director for Aesica Nottingham, commented, “Inhalation is a rapidly growing market with many U.S. companies looking to bring NCE production to Europe, whilst we also see a dramatic growth for products going into China and SE Asia, particularly amongst generic formulations. We have largely operated under the radar in terms of inhalation products despite the wealth of new technologies coming to market here and our intention is to take a lead in bringing products to market faster and developing the next generation of technologies through our Lead Technical Centre.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important